L-glutamine positive for Emmaus, commercial prospects unclear

A pharmaceutical-grade L-glutamine developed by Emmaus Life Sciences reduced the frequency of sickle cell crises and hospitalizations in a Phase III clinical trial, but questions remain about the commercial market for a product that's available as an over-the-counter supplement.

A pharmaceutical-grade L-glutamine developed by Emmaus Life Sciences reduced the frequency of sickle cell crises and hospitalizations in a Phase III clinical trial, but questions remain about the commercial market for a product that's available as an over-the-counter supplement.

Emmaus spokesman Matt Sheldon told Scrip that the purity, strength and quality of the company's L-glutamine formulation are what makes...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category